Is the business good?
How good a business is LXRX?
Lexicon Pharmaceuticals, Inc. earns −23% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
−23%
Return on invested capital · cost of capital 9.0% · 32 points below what the capital costs: growth destroys value
- Operating margin
- −35%
Operating margin · Biotechnology median −72% · 12 months to Q1 2026
- Share count, year on year
- +11%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 84%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −199% |
| FY2021 | −29225% |
| FY2022 | −72489% |
| FY2023 | −14265% |
| FY2024 | −634% |
| FY2025 | −98% |
Details›
- Gross margin12 months to Q1 2026
- 99%
- Operating margin12 months to Q1 2026
- −35%
- Net margin12 months to Q1 2026
- −37%
- R&D as % of revenue
- 84%
- Revenue, trailing twelve months
- $70M
- Net income, trailing twelve months
- −$26M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −23%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Biotechnology
The closest names by size in the same industry